Omeros Other Long-Term Assets 2010-2024 | OMER

Omeros other long-term assets from 2010 to 2024. Other long-term assets can be defined as field containing the sum of all non-current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
Omeros Annual Other Long-Term Assets
(Millions of US $)
2023 $140
2022 $124
2021 $141
2020 $1
2019 $1
2018 $1
2017 $6
2016 $6
2015 $11
2014 $1
2013 $1
2012 $1
2011 $0
2010 $0
2009 $0
Omeros Quarterly Other Long-Term Assets
(Millions of US $)
2024-06-30 $134
2024-03-31 $137
2023-12-31 $140
2023-09-30 $121
2023-06-30 $117
2023-03-31 $121
2022-12-31 $124
2022-09-30 $145
2022-06-30 $128
2022-03-31 $135
2021-12-31 $141
2021-09-30 $1
2021-06-30 $1
2021-03-31 $1
2020-12-31 $1
2020-09-30 $1
2020-06-30 $1
2020-03-31 $1
2019-12-31 $1
2019-09-30 $1
2019-06-30 $1
2019-03-31 $1
2018-12-31 $1
2018-09-30 $6
2018-06-30 $6
2018-03-31 $6
2017-12-31 $6
2017-09-30 $6
2017-06-30 $6
2017-03-31 $6
2016-12-31 $6
2016-09-30 $11
2016-06-30 $11
2016-03-31 $11
2015-12-31 $11
2015-09-30 $1
2015-06-30 $1
2015-03-31 $1
2014-12-31 $1
2014-09-30 $1
2014-06-30 $1
2014-03-31 $1
2013-12-31 $1
2013-09-30 $1
2013-06-30 $1
2013-03-31 $1
2012-12-31 $1
2012-09-30 $1
2012-06-30 $1
2012-03-31 $1
2011-12-31 $0
2011-09-30 $0
2011-06-30 $0
2011-03-31 $0
2010-12-31 $0
2010-09-30 $0
2010-06-30 $0
2010-03-31 $0
2009-12-31 $0
2009-09-30 $0
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.246B $0.000B
Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $204.059B 26.03
Stryker (SYK) United States $139.868B 31.52
Boston Scientific (BSX) United States $124.863B 35.90
Medtronic (MDT) Ireland $114.537B 17.04
EssilorLuxottica (ESLOY) France $110.799B 0.00
Lonza Group Ag (LZAGY) Switzerland $45.365B 0.00
Haleon (HLN) United Kingdom $44.180B 28.71
GE HealthCare Technologies (GEHC) United States $39.743B 20.61
ResMed (RMD) United States $35.761B 29.39
Terumo (TRUMY) Japan $28.532B 40.29
Koninklijke Philips (PHG) Netherlands $25.454B 19.48
Zimmer Biomet Holdings (ZBH) United States $21.582B 13.74
Baxter (BAX) United States $18.264B 12.39
Insulet (PODD) United States $16.648B 70.04
Smith & Nephew SNATS (SNN) United Kingdom $11.052B 0.00
Bio-Rad Laboratories (BIO) United States $10.282B 35.10
BellRing Brands (BRBR) United States $8.726B 36.90
Demant (WILYY) Denmark $8.351B 0.00
Lantheus Holdings (LNTH) United States $8.016B 19.24
ICU Medical (ICUI) United States $4.201B 40.09
TG Therapeutics (TGTX) United States $3.771B 0.00
Haemonetics (HAE) United States $3.763B 18.61
Envista Holdings (NVST) United States $3.662B 27.28
Prestige Consumer Healthcare (PBH) United States $3.657B 18.22
Perrigo (PRGO) Ireland $3.466B 10.95
Neogen (NEOG) United States $3.127B 36.08
Shandong Weigao Medical Polymer (SHWGF) China $3.010B 0.00
GN Store Nord (GNNDY) Denmark $2.988B 18.00
QuidelOrtho (QDEL) United States $2.628B 16.56
Agios Pharmaceuticals (AGIO) United States $2.557B 0.00
Green Thumb Industries (GTBIF) United States $2.260B 38.14
LeMaitre Vascular (LMAT) United States $2.165B 52.65
Curaleaf Holdings (CURLF) Canada $2.023B 0.00
Maravai LifeSciences Holdings (MRVI) United States $1.960B 0.00
Warby Parker (WRBY) United States $1.769B 0.00
AtriCure (ATRC) United States $1.641B 0.00
InMode (INMD) Israel $1.460B 8.78
AdaptHealth (AHCO) United States $1.365B 9.85
Verano Holdings (VRNOF) United States $1.231B 0.00
BioLife Solutions (BLFS) United States $1.179B 0.00
Evolus (EOLS) United States $1.036B 0.00
Owens & Minor (OMI) United States $0.925B 7.23
National Vision Holdings (EYE) United States $0.915B 29.08
Phibro Animal Health (PAHC) United States $0.906B 18.80
CeriBell (CBLL) United States $0.893B 0.00
Capricor Therapeutics (CAPR) United States $0.844B 0.00
Cresco Labs (CRLBF) United States $0.747B 0.00
VAREX IMAGING (VREX) United States $0.542B 16.36
Surmodics (SRDX) United States $0.536B 113.85
Quanterix (QTRX) United States $0.532B 0.00
Canopy Growth (CGC) Canada $0.515B 0.00
Valneva SE (VALN) France $0.475B 0.00
ZimVie (ZIMV) United States $0.398B 33.56
Viemed Healthcare (VMD) United States $0.331B 35.54
Aurora Cannabis (ACB) Canada $0.328B 0.00
OraSure Technologies (OSUR) United States $0.315B 8.12
TerrAscend (TSNDF) Canada $0.309B 0.00
Jin Medical (ZJYL) China $0.308B 0.00
Sanara MedTech (SMTI) United States $0.293B 0.00
Cerus (CERS) United States $0.290B 0.00
Biote (BTMD) United States $0.280B 12.93
Ayr Wellness (AYRWF) United States $0.279B 0.00
Zynex (ZYXI) United States $0.255B 53.33
High Tide (HITI) Canada $0.234B 97.00
MacroGenics (MGNX) United States $0.232B 0.00
Utah Medical Products (UTMD) United States $0.225B 15.14
Organigram Holdings (OGI) Canada $0.195B 0.00
Brainsway (BWAY) Israel $0.172B 206.40
FitLife Brands (FTLF) United States $0.145B 19.54
Rockwell Medical (RMTI) United States $0.121B 0.00
TriSalus Life Sciences (TLSI) United States $0.117B 0.00
Quipt Home Medical (QIPT) United States $0.113B 0.00
Veru (VERU) United States $0.107B 0.00
Oramed Pharmaceuticals (ORMP) United States $0.097B 23.90
Fonar (FONR) United States $0.092B 9.51
Jushi Holdings (JUSHF) United States $0.092B 0.00
Cellectar Biosciences (CLRB) United States $0.082B 0.00
Zevia PBC (ZVIA) United States $0.079B 0.00
InterCure (INCR) Israel $0.079B 0.00
Modular Medical (MODD) United States $0.073B 0.00
Safety Shot (SHOT) United States $0.065B 0.00
Sanuwave Health (SNWVD) United States $0.064B 1.63
MariMed (MRMD) United States $0.062B 0.00
Cytosorbents (CTSO) United States $0.047B 0.00
Allurion Technologies (ALUR) United States $0.045B 0.00
Exagen (XGN) United States $0.043B 0.00
Apyx Medical (APYX) United States $0.040B 0.00
ImmuCell (ICCC) United States $0.028B 0.00
Flora Growth (FLGC) United States $0.020B 0.00
Meihua Medical Technologies (MHUA) China $0.015B 0.00
Nephros (NEPH) United States $0.015B 0.00
Trinity Biotech (TRIB) Ireland $0.013B 0.00
Innovative Eyewear (LUCY) United States $0.013B 0.00
NeuroMetrix (NURO) United States $0.008B 0.00
GlucoTrack (GCTK) United States $0.006B 0.00
Agape ATP (ATPC) $0.006B 0.00
Sharps Technology (STSS) United States $0.005B 0.00
Leafly Holdings (LFLY) United States $0.005B 0.00
IM Cannabis (IMCC) Canada $0.004B 0.00
Akanda (AKAN) United Kingdom $0.002B 0.00
Senestech (SNES) United States $0.001B 0.00
InVivo Therapeutics Holdings (NVIVQ) United States $0.001B 0.00
United-Guardian (UG) United States $0.000B 17.87
SNDL (SNDL) Canada $0.000B 0.00